IVERIC bio, Inc. (ISEE)
| Market Cap | 928.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.27M |
| Shares Out | 93.31M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $8.95 |
| Previous Close | $8.90 |
| Change ($) | 0.05 |
| Change (%) | 0.56% |
| Day's Open | 9.04 |
| Day's Range | 8.51 - 9.19 |
| Day's Volume | 1,512,373 |
| 52-Week Range | 3.97 - 10.25 |
Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News a...
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021.
IVERIC bio (ISEE) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Iveric bio Inc (NASDAQ: ISEE) priced its underwritten public offering of 11.6 million shares at $8.60 per share, representing a discount of 4.6% from the last close price of $9.01 on Monday. Underwriter...
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it is commencing an underwritten public offering of shares of its common stock.
Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.
Iveric Bio Inc (NASDAQ: ISEE) has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of the GATHER2 trial of Zimura (avacincaptad pegol) for geograp...
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company received written agreement from the US FDA under a Special Protocol Assessment (SPA) for the design of GATHER2.
Iveric Bio Inc (NASDAQ: ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) secondary t...
NEW YORK--(BUSINESS WIRE)--Iveric Bio will present data on Zimura GATHER2 and new GATHER1 post-hoc analyses at its Dry Age-Related Macular Degeneration Virtual Symposium.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium on June 18, 2021, from 10:00 a.m. to 12:00 p.m. ET.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the quarter ended March 31, 2021 and provided a general business update.
NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to four newly hired, non-executive employees.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021.
ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021
EXTN, PSXP, ISEE, OR, and QIWI have been added to the Zacks Rank #5 (Strong Sell) List on April 21, 2021
JOBS, BUD, EURN, ISEE, and KL have been added to the Zacks Rank #5 (Strong Sell) List on April 6, 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years.
NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.
NEW YORK--(BUSINESS WIRE)--IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.
NEW YORK--(BUSINESS WIRE)--IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company's common stock.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced today that the Company will participate in upcoming virtual investor conferences in November.
Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long...
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020.
IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.
NEW YORK--(BUSINESS WIRE)--IVERIC bio granted two newly hired, non-executive employees a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.
NEW YORK--(BUSINESS WIRE)--IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.
NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced the election of Mark S. Blumenkranz, M.D.
IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News
An upsized public offering has investors increasingly confident about its prospects.
Shares of New York-based biopharma IVERIC bio Inc (NASDAQ: ISEE) were advancing strongly Monday morning on the back of a positive clinical readout.
NEW YORK, June 15, 2020 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura® (avacincaptad pego...
IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 13th
Top Ranked Momentum Stocks to Buy for May 12th
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript
About ISEE
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO David Guyer | Employees 65 |
| Stock Exchange NASDAQ | Ticker Symbol ISEE |
Analyst Forecasts
According to 3 analysts, the average rating for IVERIC bio stock is "Strong Buy." The 12-month stock price forecast is 15.33, which is an increase of 71.28% from the latest price.